Last updated on November 2017

Clinical Protocol MB102230

Brief description of study

Clinical Protocol MB102230

Detailed Study Description

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus.

Clinical Study Identifier: TX14883

Contact Investigators or Research Sites near you

Start Over

Denise Esparza

Diabetes Associates Medical Group / Clinical Research
Orange, CA USA